Status:

TERMINATED

Mesenchymal Stem Cell Transplantation in MS

Lead Sponsor:

Albert Saiz

Collaborating Sponsors:

Instituto de Salud Carlos III

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18-50 years

Phase:

PHASE2

Brief Summary

The study is a randomized Phase II study, masked and crossed-over with placebo to evaluate the safety and tolerability of autologous mesenchymal stem cell transplantation in patients with active multi...

Eligibility Criteria

Inclusion

  • Inflammatory forms of MS
  • Relapsing-remitting MS (RRMS) patients
  • Secondary progressive MS (SPMS) patients with continued relapses
  • Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive CSF (oligoclonal banding)
  • Age 18-50 years
  • Disease duration \>= 2 and \>= 10 years
  • EDSS 3.0 - 6.5
  • Progression, continued relapses or worsening MRI after at least a year of attempted therapy evidenced by:
  • Increase of \>= 1 EDSS point (if baseline EDSS \<= 5.0) or 0.5 EDSS points (if baseline EDSS \>= 5.5), or quantifiable, objective evidence of equivalent progression
  • \>= 1 moderate-severe relapses in past 18 months
  • \>= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)
  • \>= 1 new T2 lesion
  • For PPMS only, \>= 1 Gadolinium enhancing lesions
  • Has given informed consent to participate in the study.

Exclusion

  • SPMS without ongoing relapses
  • PPMS without positive CSF or Gadolinium enhancing lesions
  • \<= 3 months since treatment with any immunosuppressive therapy
  • \<=1 month since last treatment with interferon-B or glatiramer acetate
  • Corticosteroid treatment \<= 30 days
  • Relapse \<= 60 days
  • History of cancer or clinical or laboratory results indicative of severe systemic diseases, including infection for HIV, Hepatitis B or C
  • Any metallic or electronic device that precludes from undergoing MRI
  • Pregnancy or lactation
  • Current treatment with an investigational therapy

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT01228266

Start Date

December 1 2010

End Date

December 1 2013

Last Update

February 13 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Neurology Service, Hospital Clinic de barcelona

Barcelona, Barcelona, Spain, 08036

Mesenchymal Stem Cell Transplantation in MS | DecenTrialz